Prospects for the primary prevention of breast cancer

American Journal of Epidemiology

Volumn 135, Issue 2, 1992, Pages 142-152

  Bernstein, Leslie ^a   Ross, Ronald K ^a   Henderson, Brian E ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Breast neoplasms; Exercise; LH FSH releasing hormone; Primary prevention; Tamoxifen

Indexed keywords

GONADORELIN AGONIST; TAMOXIFEN;

ANOVULATION; BREAST CANCER; CANCER PREVENTION; CANCER RISK; EXERCISE; FEMALE; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; MENSTRUAL CYCLE; OSTEOPENIA; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW;

ADOLESCENT; ADULT; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; EXERCISE; FEMALE; GONADORELIN; HUMAN; MENSTRUAL CYCLE; MIDDLE AGE; OVULATION; PROGESTERONE; RECEPTORS, LHRH; SUPPORT, U.S. GOV'T, P.H.S.; TAMOXIFEN;

EID: 0026525258     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a116267     Document Type: Article

References (109)

1. Henderson BE, Ross RK, Bernstein L. Estrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1988;48:246-53.
2. Key TJA, Pike MC. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988; 24:29-43.
3. Ferrazzi E, Cartei G, De Besi P, et al. Tamoxifen in disseminated breast cancer. Tumori 1977;63: 463-8.
4. Lemer LJ, Jordan VC. Development of antiestrogens and their use in breast cancer: Eighth Cain Memorial Award Lecture. Cancer Res 1990;50: 4177-89.
5. Jordan VC. Estrogen receptor-mediated direct and indirect antitumor effects of tamoxifen. J Natl Cancer Inst 1990;82:1662-3.
6. Pollack M, Constantino J, Polychronakos C, et al. Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 1990;82:1693-7.
7. Cuzick J, Wang DY, Bulbrook RD. The prevention of breast cancer. Lancet 1986;1:83-6.
8. Love RR. Prospects for antiestrogen chemopre- vention of breast cancer. J Natl Cancer Inst 1990; 82:18-21.
9. Powles TJ, Hardy JR, Ashley SE, et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 1989;50:126-31.
10. Pike MC. Age-related factors in cancers of the breast, ovary, and endometrium. J Chronic Dis 1987;40(suppl 2):59S-69S.
11. Hsieh CC, Trichopoulos D, Katsouyanni K, et al. Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case- control study. Int J Cancer 1990;46:796-800.
12. Pike MC, Krailo MD, Henderson BE, et al. "Hormonal" risk factors, "breast tissue age" and the age incidence of breast cancer. Nature 1983;303: 767-70.
13. Trichopoulos D, MacMahon B, Cole P. The menopause and breast cancer risk. J Natl Cancer Inst 1972;48:605-13.
14. Pike MC, Ross RK, Lobo RA, et al. LHRH agonists and the prevention of breast and ovarian cancer. Br J Cancer 1989;60:142-8.
15. Spicer DV, Shoupe D, Pike MC. GnRH agonists as contraceptive agents: predicted significantly reduced risk of breast cancer. Contraception 1991; 44:289-310.
16. Messina M, Barnes S. The role of soy products in reducing risk of cancer. J Natl Cancer Inst 1991; 83:541-6.
17. Lee HP, Gourley L, Duffy SW, et al. Dietary effects on breast cancer risk in Singapore. Lancet 1991;337:1197-1200.
18. Howe GR, Hirohata T, Hislop TG, et al. Dietary factors and risk of breast cancer: combined analysis of 12 case-control studies. J Natl Cancer Inst 1990;82:561-9.
19. Rohan TE, McMichael AJ, Baghurst PA. A population-based case-control study of diet and breast cancer in Australia. Am J Epidemiol 1988; 128:478-89.
20. La Vecchia C, Decarli A, Francheschi S, et al. Dietary factors and the risk of breast cancer. Nutr Cancer 1987;10:205-14.
21. Prentice RL, Pepe M, Self SG. Dietary fat and breast cancer: a quantitative assessment of the epidemiological literature and a discussion of methodological issues. Cancer Res 1989;49: 3147-56.
22. Prentice RL, Kakar F, Hursting S, et al. Aspects of the rationale of the Women's Health Trial. J Natl Cancer Inst 1988;80:802-14.
23. MacMahon B, Trichopoulos D, Brown J, et al. Age at menarche, probability of ovulation and breast cancer risk. Int J Cancer 1982;29:13-16.
24. Vihko R, Apter D. Endocrine characteristics of adolescent menstrual cycles: impact of early menarche. J Steroid Biochem 1984;20:231-6.
25. Henderson BE, Ross RK, Judd HL, et al. Do regular ovulatory cycles increase breast cancer risk? Cancer 1985;56:1206-8.
26. La Vecchia C, Decarli A, DiPietro S, et al. Menstrual cycle patterns and the risk of breast disease. Eur J Cancer Clin Oncol 1985;21:417-22.
27. Treloar AE, Boynton RE, Behn BG, et al. Variation of the human menstrual cycle through reproductive life. Int J Fertil 1967;12:77-126.
28. Matsumoto S, Nogami Y, Ohkuri S. Statistical studies of menstruation: a criticism of the definition of normal menstruation. Gunma J Med Sci 1962;11:294-318.
29. Brown JB. Hormone profiles in young women at risk of breast cancer: a study of ovarian function during theelarche, menarche, and menopause and after childbirth. In: Pike MC, Suteri PK, Welsch CW, eds. Hormones and breast cancer. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1981:33-54.
30. Henderson BE, Pike MC, Casagrande JT. Breast cancer and the estrogen window hypothesis. Lancet 1981;2:363-4.
31. Doring GK. The incidence of anovulatory cycles in women. J Reprod Fertil 1969;6(suppl):77-81.
32. Apter D. Serum steroids and pituitary hormones in female puberty: a partly longitudinal study. Clin Endocrinol 1980;12:107-20.
33. Metcalf MG, Skidmore DS, Lowry GF, et al. Incidence of ovulation in the years after menarche. J Endocrinol 1983;97:213-19.
34. Apter D, Vihko R. Early menarche, a risk factor for breast cancer, indicates early onset of ovulatory cycles. J Clin Endocrinol Metab 1983;57:82-6.
35. Bernstein L, Ross R, Lobo RA, et al. The effects of moderate physical activity on menstrual cycle patterns in adolescence: implications for breast cancer prevention. Br J Cancer 1987;55:681-5.
36. Apter D, Bolton NJ, Hammond GL, et al. Serum sex hormone-binding globulin during puberty in girls and in different types of adolescent menstrual cycles. Acta Endocrinol (Copenh) 1984;107: 413-19.
37. Apter D, Reinila M, Vihko R. Some endocrine characteristics of early menarche, a risk factor for breast cancer, are preserved into adulthood. Int J Cancer 1989;44:783-7.
38. Frisch RE, Wyshak G, Vincent L. Delayed menarche and amenorrhea in ballet dancers. N Engl J Med 1980;303:17-19.
39. Frisch RE, Gotz-Welbergen AV, McArthur JW, et al. Delayed menarche and amenorrhea of college athletes in relation to age at onset of training. JAMA 1981;246:1559-63.
40. Moisan J, Meyer F, Gingras S. A nested case- control study of the correlates of early menarche. Am J Epidemiol 1990;132:953-61.
41. Feicht CB, Johnson TS, Martic BJ, et al. Secondary amenorrhea in athletes. Lancet 1978;2: 1145-6.
42. Wakat DK, Sweeney KA, Rogol AD. Reproductive system function in women cross-country runners. Med Sci Sports Exerc 1982;14:263-9.
43. Russel JB, Mitchell D, Mussey PI, et al. The relationship of exercise to anovulatory cycles in female athletes: hormonal and physical characteristics. Obstet Gynecol 1984;63:452-6.
44. Frisch RE, Wyshak G, Albright NL, et al. Lower prevalence of breast cancer and cancers of the reproductive system among former college athletes compared to nonathletes. Br J Cancer 1985; 52:885-91.
45. Apter D, Vihko V, Pukkala E, et al. Physical activity and risk for breast cancer: observations on physical education and language teachers. Presented at the Fourth Scandinavian Breast Cancer Symposium, Porvoo, Finland, June 1991.
46. Warren MP, Brooks-Gunn J, Hamilton LH, et al. Scoliosis and fractures in young ballet dancers: relation to delayed menarche and secondary amenorrhea. N Engl J Med 1986;314:1348-53.
47. van Noord PAH, Kaaks R. The effect of wartime conditions and the 1944-45 "Dutch Famine" on recalled menarcheal age in participants of the DOM breast cancer screening project. Ann Hum Biol 1991;18:57-70.
48. Satyanarayana K, Nadami Nadu A. Nutrition and menarche in rural Hyderabad. Ann Hum Biol 1979;2:163-5.
49. Dreizen S, Spirakis CN, Stone RE. A comparison of skeletal growth and maturation in undernourished and well-nourished girls before and after menarche. J Pediatr 1967;70:256-64.
50. Hoel DG, Wakabayashi T, Pike MC. Secular trends in the distributions of the breast cancer risk factors-menarche, first birth, menopause, and weight-in Hiroshima and Nagasaki, Japan. Am J Epidemiol 1983;118:78-89.
51. Meyer F, Moisan J, Marcoux D, et al. Dietary determinants of menarche. (Abstract). Am J Epidemiol 1987;126:762.
52. Hill P, Wynder E, Garbaczewski L, et al. Diet and menarche in different ethnic groups. Eur J Cancer 1980;16:519-25.
53. Richardson BD, Laing PM, Rantsho JM, et al. The bearing of diverse patterns of diet on growth and menarche in four ethnic groups of South African girls. J Trap Med Hyg 1983;86:5-12.
54. Kralj-Cercek L. The influence of food, body build, and social origin on the age at menarche. Hum Biol 1956;28:393-406.
55. Sanchez A, Kissinger DG, Phillips RI. A hypothesis on the etiological role of diet on age of menarche. Med Hypotheses 1981;7:1339-45.
56. Kissinger DG, Sanchez A. The association of dietary factors with the age of menarche. Nutr Res 1987;7:471-9.
57. Hughes RE, Jones E. Intake of dietary fibre and the age of menarche. Ann Hum Biol 1985;4: 325-32.
58. Meyer F, Moisan J, Marcoux D, et al. Dietary and physical determinants of menarche. Epidemiology 1990;1:377-81.
59. Schwartz SM, Wilson ME, Walker ML, et al. Dietary influences on growth and sexual maturation in premenarchial rhesus monkeys. Horm Be- hav 1988;22:231-51.
60. Mann RD, ed. Oral contraceptives and breast cancer. Park Ridge, NJ: Parthenon Publishing Group, 1990.
61. Nicholson RI, Walker KJ, Maynard PV. Antitumour potential of a new potent luteinizing hormone releasing hormone analogue, ICI 118630. Eur J Cancer 1980;suppl 1:295-9.
62. Harvey HA, Lipton A, Max DT, et al. Medical castration produced by the GnRH analogue leu- prolide to treat metastatic breast cancer. J Clin Oncol 1985;3:1068-72.
63. Williams MR, Walker KJ, Turkes A, et al. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 1986;53:629-36.
64. Dixon AR, Robertson JFR, Jackson L, et al. Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival. Br J Cancer 1990;62:868-70.
65. Gudmundsson JA, Nillius SJ, Bergquist C. Intranasal peptide contraception by inhibition of ovulation with the gonadotropin-releasing hormone superagonist nafarelin: six months' clinical results. Fertil Steril 1986;45:617-23.
66. McLachlan RI, Healy DL, Burger HG. Clinical aspects of LHRH analogues in gynaecology: a review. Br J Obstet Gynaecol 1986;45:617-23.
67. Henderson BE, Ross RK, Lobo RA, et al. Reevaluating the role of progestogen therapy after the menopause. Fertil Steril 1988;59(suppl):9-15.
68. Ross RK, Pike MC, Henderson BE, et al. Stroke prevention and oestrogen replacement therapy. (Letter). Lancet 1989; 1:505.
69. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med 1988;319:1681-92.
70. Spicer D, Pike MC, Henderson BE. The question of estrogen replacement therapy in patients with a prior diagnosis of breast cancer. Oncology 1990; 4:49-59.
71. Nolvadex and Adjuvant Trial Organization (NATO). Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 1988;57:608-11.
72. Ribeiro G, Swindell R. The Christie Hospital adjuvant tamoxifen trial: status at 10 years. Br J Cancer 1988;57:601-3.
73. Fisher B, Constantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-84.
74. Fomander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;1: 117-20.
75. Stewart HJ, Knight GM. Tamoxifen and the uterus and endometrium. (Letter). Lancet 1989; 1:375-6.
76. Jordan VC. Tamoxifen for the prevention of breast cancer. In: DeVita VT, Heilman S, Rosenberg SA, eds. Cancer prevention. Philadelphia: JB Lippincott Company, 1990:1-12.
77. Kannel WB, Hjortland MC, McNamara PM, et al. Menopause and risk of cardiovascular disease. Ann Intern Med 1976;85:447-52.
78. Ross RK, Pike MC, Mack TM, et al. Oestrogen replacement therapy and cardiovascular disease. In: Drife JO, Studd JWW, eds. HRT and osteoporosis. London: Springer-Verlag, 1990:209-22.
79. Barrett-Connor E, Bush TJ. Estrogen and coronary heart disease in women. JAMA 1991;265: 1861-7.
80. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ 1988;297:519-22.
81. Love RR, Newcomb PA, Wiebe DA, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with nodenegative breast cancer. J Natl Cancer Inst 1990: 82:1327-32.
82. Roessner S, Wallgren A. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 1984;52:339-46.
83. Bertelli B, Pronzato P, Amoroso D, et al. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 1988;12:307-10.
84. Bruning PF, Bonfrer JMG, Hart AAM, et al. Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 1988;58:497-9.
85. Sedlacek S. Estrogenic properties of tamoxifen on serum lipids in postmenopausal women with breast cancer. (Abstract). Breast Cancer Res Treat 1989; 14:153. (Abstract no. 82).
86. Stewart HJ. The Scottish Adjuvant Tamoxifen Trials. Presented at the NIH Consensus Development Conference on Early Stage Breast Cancer, Bethesda, MD, June 1990.
87. Stewart HJ. Scottish Adjuvant Tamoxifen Trial. Presented at the Fourth Scandinavian Breast Cancer Symposium, Porvoo, Finland, June 1991.
88. Love RR, Mazess RB, Tomey DC, et al. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 1988;12:297-301.
89. Turken S, Siris E, Seldin D, et al. Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 1989;81: 1086-8.
90. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving tamoxifen. Cancer Treat Rep 1985;69: 127-8.
91. Hardell L. Tamoxifen as risk factor for carcinoma of corpus uteri. (Letter). Lancet 1988;2:563.
92. Hardell L. Pelvic irradiation and tamoxifen as risk factors for carcinoma of corpus uteri. (Letter). Lancet 1988;2:1432.
93. Mathew A, Chabon AB, Kabakow B, et al. Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy. N Y State J Med 1990;90:207-8.
94. Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen and radiotherapy for early breast cancer. Presented at the Fourth Scandinavian Breast Cancer Symposium, Porvoo, Finland, June 1991.
95. Groom GV, Griffiths K. Effect of the antioestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal premenopausal women. J Endocrinol 1976;70: 421-8.
96. Fukushima T, Tajima C, Fukuma K, et al. Tamoxifen in the treatment of infertility associated with luteal phase deficiency. Fertil Steril 1986;37: 755-61.
97. Williamson JG, Ellis JD. The induction of ovulation by tamoxifen. J Obstet Gynaecol Br Com- monw 1973;80:844-7.
98. Boccardo F, Bruzzi P, Rubagotti A, et al. Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology 1981;38: 281-5.
99. Boccardo F, Guamieri D, Rubagotti A, et al. Endocrine effects of tamoxifen in postmenopausal breast cancer patients. Tumori 1984;70:61-8.
100. Satyaswaroop PG, Zaino RJ, Mortel R. Estrogenlike effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 1984;44:4006-10.
101. Gottardis MM, Robinson SP, Satyaswaroop PS, et al. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988;48:812-15.
102. Jordan VC. Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. Cancer Treat Rep 1976;60:1409-19.
103. Anzai Y, Holinka CF, Kuramoto H, et al. Stimulatory effects of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line). Cancer Res 1989;49: 2362-5.
104. Yager JD, Yager R. Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats. Cancer Res 1980;40: 3680-5.
105. Lipton A, Harvey HA, Hamilton RW. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 1984;68:887-9.
106. Falkson HC, Gray R, Wolberg WH, et al. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. J Clin Oncol 1990;8: 599-607.
107. Jordan VC, Fritz NF, Tormey DC. Long-term adjuvant therapy with tamoxifen effects on sex hormone binding globulin and antithrombin III. Cancer Res 1987;47:4517-19.
108. Powles TJ, Tillyer CR, Jones AL, et al. Prevention of breast cancer with tamoxifen: an update on the Royal Marsden Hospital pilot programme. Eur J Cancer 1990;26:680-4.
109. Cuzick J, Berridge D, Whitehead J. Mammo- graphic dysplasia as entry criterion for breast cancer prevention trials. (Letter). Lancet 1991;337: 1225.